main content start

Homepage

Latest Videos

Latest Videos

Brightcove Home Latest Listing

Breast Cancer

Breast Cancer

Brightcove Cards Listing

Prostate Cancer

Brightcove Cards Listing

Multiple Myeloma

Multiple Myeloma

Brightcove Cards Listing

Popular on MedEnrich

Popular in No name
  • Myelodysplastic Syndromes17m 59s

    Genomics of AML -Therapeutic and Prognostic Implications

    ~40% of AML patients have targetable mutations. Younger patients often have FLT3-ITD or FLT3- TKD mutation. Mutations IDH-1 , IDH-2 & t-53 mutations are more common in elderly patients.
    idh 1& 2 mutations flt3-tkd mutations bcl2 inhibtors genomics of aml
  • Breast Cancer3m 36s

    Tumor Infiltrating Lymphocytes as Predictive Biomarker in Breast Cancer

    Immune cells known as tumor-infiltrating lymphocytes (TILs) are thought to be a promising, affordable biomarker with prognostic and predictive potential.
    tumor-infiltrating lymphocytes (tils) promising biomarker
  • Myelodysplastic Syndromes3m 14s

    Low Risk MDS - Key Practice Points

    Myelodysplastic Syndromes (MDS) or Myeloproliferative Neoplasms show considerable heterogeneity with respect to presence of anemia , cytopenia & molecular features.
    ipss -m low risk molecular features
  • "NA"11m 43s

    Sequencing of treatment for Her2 positive MBC in 2022

    Noteworthy treatment options added in the treatment guidelines for Her2 positive MBC are Trastuzumab Deruxtecan (TDXd) and combination of Trastuzumab + Capecitabine +Tucatinib.
    brain metastases her2 positive mbc trastuzumab deruxtecan tucatinib
  • Multiple-Myeloma0m 53s

    Importance of identifying High Risk Patients in Multiple Myeloma

    High risk disease is observed in 30% of Myeloma Cases. Identification of high-risk patients is important as proportion of high-risk cases increase with relapses and can lead to significant mortality.
    high risk myeloma
  • Multiple Myeloma4m 12s

    Key Practice Points -Myeloma Related Renal Impairment

    In patients with renal impairment primary goal is improvement of Renal Function which is associated with improved treatment outcomes. 50% of patients present renal impairment and renal impairment is severe in 15% of patients.
    myeloma renal impairment key practice points
  • Breast Cancer29m 30s

    SABCS Update 2022

    Summary of Key Abstracts from SABCS 2022
    recurrence score tailor-x destiny breast 03 adjuvant cdk4/6 inhibitor antibody drug conjugates
  • Breast Cancer8m 55s

    Understanding HER-2 Low Breast Cancer Entity & Treatment Strategy

    Tumors with a HER-2 immunohistochemistry (IHC) score of 1 + or 2 + and a negative molecular reflex test have been classified as HER2-low Breast Cancers.
    trastuzumab-deruxtecan (t-dxd) her2 low breast cancers
  • Multiple Myeloma10m 40s

    Recommendations -Management of Myeloma Related Renal Impairment

    Supportive Care, Mechanical Approach and Systemic Antimyeloma treatment are 3 pillars of management of Myeloma related renal impairment. In supportive care prompt initiation of high fluid administration, appropriate use of Bisphosphonates can help.
    myeloma renal impairment lancet guidelines
  • Critical Care11m 27s

    Preventing or reversing vascular calcifications in high risk Chronic kidney disease (CKD) patients

    In this video, Dr. Floege talks about the mechanisms of vascular calcifications in patients at high risk of CKD and measures to prevent or reverse the same.
    chronic kidney disease vascular calcification vitamin k1 magnesium oxide matrix-gla protein
  • For Pharmacist

    For Pharmacist

    Brightcove Cards Listing

    Webinars

    Webinar Cards Listing

    MedBytes

    MedBytes

    Medbytes Cards Listing
    Hi, can I help?
    Chat SupportX
    Support Team
    Hello, how can I help you today?
    Please select one of the below options.

    Find Information

    Unable to Login or Register

    Want to share feedback